We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 02, 2020

Early Treatment With Tocilizumab and Mortality in COVID-19

JAMA internal medicine


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA internal medicine
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
JAMA Intern Med 2020 Oct 20;[EPub Ahead of Print], S Gupta, W Wang, SS Hayek, L Chan, KS Mathews, ML Melamed, SK Brenner, A Leonberg-Yoo, EJ Schenck, J Radbel, J Reiser, A Bansal, A Srivastava, Y Zhou, D Finkel, A Green, M Mallappallil, AJ Faugno, J Zhang, JCQ Velez, S Shaefi, CR Parikh, DM Charytan, AM Athavale, AN Friedman, RE Redfern, SAP Short, S Correa, KK Pokharel, AJ Admon, JP Donnelly, HB Gershengorn, DJ Douin, MW Semler, MA Hernán, DE Leaf, STOP-COVID Investigators

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading